Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 50 entries
Sorted by: Best Match Show Resources per page
HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.

JCI insight

Wu G, Swanson M, Talla A, Graham D, Strizki J, Gorman D, Barnard RJ, Blair W, Søgaard OS, Tolstrup M, Østergaard L, Rasmussen TA, Sekaly RP, Archin NM, Margolis DM, Hazuda DJ, Howell BJ.
PMID: 28814661
JCI Insight. 2017 Aug 17;2(16). doi: 10.1172/jci.insight.92901. eCollection 2017 Aug 17.

Promising therapeutic approaches for eradicating HIV include transcriptional activation of provirus from latently infected cells using latency-reversing agents (LRAs) and immune-mediated clearance to purge reservoirs. Accurate detection of cells capable of producing viral antigens and virions, and the measurement...

Cite
Wu G, Swanson M, Talla A, et al. HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. JCI Insight. 2017;2(16)doi: 10.1172/jci.insight.92901.
Wu, G., Swanson, M., Talla, A., Graham, D., Strizki, J., Gorman, D., Barnard, R. J., Blair, W., Søgaard, O. S., Tolstrup, M., Østergaard, L., Rasmussen, T. A., Sekaly, R. P., Archin, N. M., Margolis, D. M., Hazuda, D. J., & Howell, B. J. (2017). HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. JCI insight, 2(16), . https://doi.org/10.1172/jci.insight.92901
Wu, Guoxin, et al. "HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal." JCI insight vol. 2,16 (2017). doi: https://doi.org/10.1172/jci.insight.92901
Wu G, Swanson M, Talla A, Graham D, Strizki J, Gorman D, Barnard RJ, Blair W, Søgaard OS, Tolstrup M, Østergaard L, Rasmussen TA, Sekaly RP, Archin NM, Margolis DM, Hazuda DJ, Howell BJ. HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. JCI Insight. 2017 Aug 17;2(16). doi: 10.1172/jci.insight.92901. eCollection 2017 Aug 17. PMID: 28814661; PMCID: PMC5621903.
Copy Download .nbib Format: NLM
Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Marconi VC, Moser C, Gavegnano C, Deeks SG, Lederman MM, Overton ET, Tsibris A, Hunt PW, Kantor A, Sekaly RP, Tressler R, Flexner C, Hurwitz SJ, Moisi D, Clagett B, Hardin WR, Del Rio C, Schinazi RF, Lennox JJ.
PMID: 33693561
Clin Infect Dis. 2022 Jan 07;74(1):95-104. doi: 10.1093/cid/ciab212.

BACKGROUND: Inflammation is associated with end-organ disease and mortality for people with human immunodeficiency virus (PWH). Ruxolitinib, a Jak 1/2 inhibitor, reduces systemic inflammation for individuals without human immunodeficiency virus (HIV) and HIV reservoir markers ex vivo. The goal...

Cite
Marconi VC, Moser C, Gavegnano C, et al. Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2022;74(1):95-104doi: 10.1093/cid/ciab212.
Marconi, V. C., Moser, C., Gavegnano, C., Deeks, S. G., Lederman, M. M., Overton, E. T., Tsibris, A., Hunt, P. W., Kantor, A., Sekaly, R. P., Tressler, R., Flexner, C., Hurwitz, S. J., Moisi, D., Clagett, B., Hardin, W. R., Del Rio, C., Schinazi, R. F., & Lennox, J. J. (2022). Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 74(1), 95-104. https://doi.org/10.1093/cid/ciab212
Marconi, Vincent C, et al. "Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 74,1 (2022): 95-104. doi: https://doi.org/10.1093/cid/ciab212
Marconi VC, Moser C, Gavegnano C, Deeks SG, Lederman MM, Overton ET, Tsibris A, Hunt PW, Kantor A, Sekaly RP, Tressler R, Flexner C, Hurwitz SJ, Moisi D, Clagett B, Hardin WR, Del Rio C, Schinazi RF, Lennox JJ. Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2022 Jan 07;74(1):95-104. doi: 10.1093/cid/ciab212. PMID: 33693561; PMCID: PMC8752257.
Copy Download .nbib Format: NLM
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients.

Nature communications

Maschan M, Caimi PF, Reese-Koc J, Sanchez GP, Sharma AA, Molostova O, Shelikhova L, Pershin D, Stepanov A, Muzalevskii Y, Suzart VG, Otegbeye F, Wald D, Xiong Y, Wu D, Knight A, Oparaocha I, Ferencz B, Roy A, Worden A, Kruger W, Kadan M, Schneider D, Orentas R, Sekaly RP, de Lima M, Dropulić B.
PMID: 34893603
Nat Commun. 2021 Dec 10;12(1):7200. doi: 10.1038/s41467-021-27312-6.

Chimeric antigen receptor (CAR) T cells targeting the CD19 antigen are effective in treating adults and children with B-cell malignancies. Place-of-care manufacturing may improve performance and accessibility by obviating the need to cryopreserve and transport cells to centralized facilities....

Cite
Maschan M, Caimi PF, Reese-Koc J, et al. Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nat Commun. 2021;12(1):7200doi: 10.1038/s41467-021-27312-6.
Maschan, M., Caimi, P. F., Reese-Koc, J., Sanchez, G. P., Sharma, A. A., Molostova, O., Shelikhova, L., Pershin, D., Stepanov, A., Muzalevskii, Y., Suzart, V. G., Otegbeye, F., Wald, D., Xiong, Y., Wu, D., Knight, A., Oparaocha, I., Ferencz, B., Roy, A., Worden, A., Kruger, W., Kadan, M., Schneider, D., Orentas, R., Sekaly, R. P., de Lima, M., & Dropulić, B. (2021). Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nature communications, 12(1), 7200. https://doi.org/10.1038/s41467-021-27312-6
Maschan, Michael, et al. "Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients." Nature communications vol. 12,1 (2021): 7200. doi: https://doi.org/10.1038/s41467-021-27312-6
Maschan M, Caimi PF, Reese-Koc J, Sanchez GP, Sharma AA, Molostova O, Shelikhova L, Pershin D, Stepanov A, Muzalevskii Y, Suzart VG, Otegbeye F, Wald D, Xiong Y, Wu D, Knight A, Oparaocha I, Ferencz B, Roy A, Worden A, Kruger W, Kadan M, Schneider D, Orentas R, Sekaly RP, de Lima M, Dropulić B. Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nat Commun. 2021 Dec 10;12(1):7200. doi: 10.1038/s41467-021-27312-6. PMID: 34893603.
Copy Download .nbib Format: NLM
Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines.

Current opinion in virology

Pelletier AN, Sekaly RP, Tomalka JA.
PMID: 34902803
Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10.

The SARS-CoV-2 pandemic has highlighted how an emergent disease can spread globally and how vaccines are once again the most important public health policy to combat infectious disease. Despite promising initial protection, the rise of new viral variants calls...

Cite
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021;52:89-101doi: 10.1016/j.coviro.2021.11.012.
Pelletier, A. N., Sekaly, R. P., & Tomalka, J. A. (2021). Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Current opinion in virology, 5289-101. https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier, Adam N, et al. "Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines." Current opinion in virology vol. 52 (2021): 89-101. doi: https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10. PMID: 34902803.
Copy Download .nbib Format: NLM
Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection.

Translational research : the journal of laboratory and clinical medicine

Latif MB, Shukla S, Del Rio Estrada PM, Ribeiro SP, Sekaly RP, Sharma AA.
PMID: 34871809
Transl Res. 2021 Dec 03; doi: 10.1016/j.trsl.2021.12.001. Epub 2021 Dec 03.

Patients with cancers have been severely affected by the COVID-19 pandemic. This is highlighted by the adverse outcomes in cancer patients with COVID-19 as well as by the impact of the COVID-19 pandemic on cancer care. Patients with cancer...

Cite
Latif MB, Shukla S, Del Rio Estrada PM, et al. Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection. Transl Res. 2021;doi: 10.1016/j.trsl.2021.12.001.
Latif, M. B., Shukla, S., Del Rio Estrada, P. M., Ribeiro, S. P., Sekaly, R. P., & Sharma, A. A. (2021). Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection. Translational research : the journal of laboratory and clinical medicine, . https://doi.org/10.1016/j.trsl.2021.12.001
Latif, Muhammad Bilal, et al. "Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection." Translational research : the journal of laboratory and clinical medicine vol. (2021). doi: https://doi.org/10.1016/j.trsl.2021.12.001
Latif MB, Shukla S, Del Rio Estrada PM, Ribeiro SP, Sekaly RP, Sharma AA. Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection. Transl Res. 2021 Dec 03; doi: 10.1016/j.trsl.2021.12.001. Epub 2021 Dec 03. PMID: 34871809; PMCID: PMC8641406.
Copy Download .nbib Format: NLM
Nonstructured Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs.

The Journal of infectious diseases

Kirk GD, Astemborski J, Mehta SH, Ritter KD, Laird GM, Bordi R, Sekaly R, Siliciano JD, Siliciano RF.
PMID: 33037877
J Infect Dis. 2021 Jun 04;223(11):1905-1913. doi: 10.1093/infdis/jiaa634.

The latent reservoir for human immunodeficiency virus type 1 (HIV-1) in CD4+ T cells is a major barrier to cure. HIV-1-infected persons who inject drugs (PWID) often struggle to maintain suppression of viremia and experience nonstructured treatment interruptions (NTIs)....

Cite
Kirk GD, Astemborski J, Mehta SH, et al. Nonstructured Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs. J Infect Dis. 2021;223(11):1905-1913doi: 10.1093/infdis/jiaa634.
Kirk, G. D., Astemborski, J., Mehta, S. H., Ritter, K. D., Laird, G. M., Bordi, R., Sekaly, R., Siliciano, J. D., & Siliciano, R. F. (2021). Nonstructured Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs. The Journal of infectious diseases, 223(11), 1905-1913. https://doi.org/10.1093/infdis/jiaa634
Kirk, Gregory D, et al. "Nonstructured Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs." The Journal of infectious diseases vol. 223,11 (2021): 1905-1913. doi: https://doi.org/10.1093/infdis/jiaa634
Kirk GD, Astemborski J, Mehta SH, Ritter KD, Laird GM, Bordi R, Sekaly R, Siliciano JD, Siliciano RF. Nonstructured Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs. J Infect Dis. 2021 Jun 04;223(11):1905-1913. doi: 10.1093/infdis/jiaa634. PMID: 33037877; PMCID: PMC8176633.
Copy Download .nbib Format: NLM
Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines.

Current opinion in virology

Pelletier AN, Sekaly RP, Tomalka JA.
PMID: 34902803
Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10.

The SARS-CoV-2 pandemic has highlighted how an emergent disease can spread globally and how vaccines are once again the most important public health policy to combat infectious disease. Despite promising initial protection, the rise of new viral variants calls...

Cite
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021;52:89-101doi: 10.1016/j.coviro.2021.11.012.
Pelletier, A. N., Sekaly, R. P., & Tomalka, J. A. (2021). Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Current opinion in virology, 5289-101. https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier, Adam N, et al. "Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines." Current opinion in virology vol. 52 (2021): 89-101. doi: https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10. PMID: 34902803; PMCID: PMC8664555.
Copy Download .nbib Format: NLM
Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines.

Current opinion in virology

Pelletier AN, Sekaly RP, Tomalka JA.
PMID: 34902803
Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10.

The SARS-CoV-2 pandemic has highlighted how an emergent disease can spread globally and how vaccines are once again the most important public health policy to combat infectious disease. Despite promising initial protection, the rise of new viral variants calls...

Cite
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021;52:89-101doi: 10.1016/j.coviro.2021.11.012.
Pelletier, A. N., Sekaly, R. P., & Tomalka, J. A. (2021). Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Current opinion in virology, 5289-101. https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier, Adam N, et al. "Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines." Current opinion in virology vol. 52 (2021): 89-101. doi: https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10. PMID: 34902803; PMCID: PMC8664555.
Copy Download .nbib Format: NLM
Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines.

Current opinion in virology

Pelletier AN, Sekaly RP, Tomalka JA.
PMID: 34902803
Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10.

The SARS-CoV-2 pandemic has highlighted how an emergent disease can spread globally and how vaccines are once again the most important public health policy to combat infectious disease. Despite promising initial protection, the rise of new viral variants calls...

Cite
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021;52:89-101doi: 10.1016/j.coviro.2021.11.012.
Pelletier, A. N., Sekaly, R. P., & Tomalka, J. A. (2021). Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Current opinion in virology, 5289-101. https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier, Adam N, et al. "Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines." Current opinion in virology vol. 52 (2021): 89-101. doi: https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10. PMID: 34902803; PMCID: PMC8664555.
Copy Download .nbib Format: NLM
Anisocytosis is Associated With Short-Term Mortality in COVID-19 and May Reflect Proinflammatory Signature in Uninfected Ambulatory Adults.

Pathogens & immunity

Hornick A, Tashtish N, Osnard M, Shah B, Bradigan A, Albar Z, Tomalka J, Dalton J, Sharma A, Sekaly RP, Hejal R, Simon DI, Zidar DA, Al-Kindi SG.
PMID: 33089037
Pathog Immun. 2020 Oct 02;5(1):312-326. doi: 10.20411/pai.v5i1.391. eCollection 2020.

BACKGROUND: Red cell distribution width (RDW), a measure of anisocytosis, is observed in chronic inflammation and is a prognostic marker in critically ill patients without COVID-19, but data in COVID-19 are limited.METHODS: Between March 12 and April 19, 2020,...

Cite
Hornick A, Tashtish N, Osnard M, et al. Anisocytosis is Associated With Short-Term Mortality in COVID-19 and May Reflect Proinflammatory Signature in Uninfected Ambulatory Adults. Pathog Immun. 2020;5(1):312-326doi: 10.20411/pai.v5i1.391.
Hornick, A., Tashtish, N., Osnard, M., Shah, B., Bradigan, A., Albar, Z., Tomalka, J., Dalton, J., Sharma, A., Sekaly, R. P., Hejal, R., Simon, D. I., Zidar, D. A., Al-Kindi, S. G. (2020). Anisocytosis is Associated With Short-Term Mortality in COVID-19 and May Reflect Proinflammatory Signature in Uninfected Ambulatory Adults. Pathogens & immunity, 5(1), 312-326. https://doi.org/10.20411/pai.v5i1.391
Hornick, Andrew, et al. "Anisocytosis is Associated With Short-Term Mortality in COVID-19 and May Reflect Proinflammatory Signature in Uninfected Ambulatory Adults." Pathogens & immunity vol. 5,1 (2020): 312-326. doi: https://doi.org/10.20411/pai.v5i1.391
Hornick A, Tashtish N, Osnard M, Shah B, Bradigan A, Albar Z, Tomalka J, Dalton J, Sharma A, Sekaly RP, Hejal R, Simon DI, Zidar DA, Al-Kindi SG. Anisocytosis is Associated With Short-Term Mortality in COVID-19 and May Reflect Proinflammatory Signature in Uninfected Ambulatory Adults. Pathog Immun. 2020 Oct 02;5(1):312-326. doi: 10.20411/pai.v5i1.391. eCollection 2020. PMID: 33089037; PMCID: PMC7556412.
Copy Download .nbib Format: NLM
Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines.

Current opinion in virology

Pelletier AN, Sekaly RP, Tomalka JA.
PMID: 34902803
Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10.

The SARS-CoV-2 pandemic has highlighted how an emergent disease can spread globally and how vaccines are once again the most important public health policy to combat infectious disease. Despite promising initial protection, the rise of new viral variants calls...

Cite
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021;52:89-101doi: 10.1016/j.coviro.2021.11.012.
Pelletier, A. N., Sekaly, R. P., & Tomalka, J. A. (2021). Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Current opinion in virology, 5289-101. https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier, Adam N, et al. "Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines." Current opinion in virology vol. 52 (2021): 89-101. doi: https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10. PMID: 34902803; PMCID: PMC8664555.
Copy Download .nbib Format: NLM
Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines.

Current opinion in virology

Pelletier AN, Sekaly RP, Tomalka JA.
PMID: 34902803
Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10.

The SARS-CoV-2 pandemic has highlighted how an emergent disease can spread globally and how vaccines are once again the most important public health policy to combat infectious disease. Despite promising initial protection, the rise of new viral variants calls...

Cite
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021;52:89-101doi: 10.1016/j.coviro.2021.11.012.
Pelletier, A. N., Sekaly, R. P., & Tomalka, J. A. (2021). Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Current opinion in virology, 5289-101. https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier, Adam N, et al. "Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines." Current opinion in virology vol. 52 (2021): 89-101. doi: https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10. PMID: 34902803; PMCID: PMC8664555.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 50 entries